Corrected: BRIEF-Halozyme Therapeutics Q4 Adjusted EPS USD -0.24 Vs. IBES Estimate USD 2.2
17/02/2026 21:01
Feb 17 (Reuters) - Halozyme Therapeutics Q4 EPS USD -1.2. Q4 net income USD -141.6 million outlook FY revenue USD 1,710-1,810 million
Recent news on Halozyme Therapeutics
See all newsUS RESEARCH ROUNDUP-BlackRock, Evercore, Goldman Sachs
Halozyme wins court order to block Merck's injected Keytruda in select European markets (updated)
US STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
Halozyme wins court order to block Merck's injected Keytruda in select European markets